CBU
TVTX icon

CIBC Bancorp USA’s Travere Therapeutics TVTX Stock Holding History

CIBC Bancorp USA’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$225K Buy
+9,398
New +$177K ﹤0.01% 1215

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CIBC Bancorp USA's TVTX Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Travere Therapeutics (TVTX) in Q3 2025: 9,398 shares worth $225K. The stake represents ﹤0.01% of the portfolio and ranks #1215 among its holdings.

238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • CIBC Bancorp USA held 9,398 shares of Travere Therapeutics worth $225K as of Q3 2025.
  • Travere Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Travere Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1215 holding.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.